Bionano Genomics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| AdditionalPaid-inCapital · AccumulatedDeficit · Accumulated Other Comprehensive Income (Loss) · TotalStockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock | |||||||
| Shares · Amount | |||||||
| Balance at January 1, 2023 | 495,300 | $— | $599,239,000 | $(348,715,000) | $(1,124,000) | $249,400,000 | |
| Stock option exercises | 100 | — | 23,000 | — | — | 23,000 | |
| Stock-based compensation expense | — | — | 15,178,000 | — | — | 15,178,000 | |
| Issue common stock, net of issuance costs | 208,500 | — | 56,313,000 | — | — | 56,313,000 | |
| Issue stock for employee stock purchase plan | 500 | — | 108,000 | — | — | 108,000 | |
| Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes | — | — | (61,000) | — | — | (61,000) | |
| Issuance of common stock for High Trail convertible notes payable | 58,200 | — | 6,542,000 | 6,542,000 | |||
| Net loss | — | — | — | (232,493,000) | — | (232,493,000) | |
| Other comprehensive loss | — | — | — | — | 1,147,000 | 1,147,000 | |
| Balance at December 31, 2023 | 762,600 | $— | $677,342,000 | $(581,208,000) | $23,000 | $96,157,000 | |
| Stock-based compensation expense | — | — | 9,736,000 | — | — | 9,736,000 | |
| Issue common stock and warrants, net of issuance costs | 968,600 | — | 41,481,000 | — | — | 41,481,000 | |
| Issue stock for warrant exercises | 133,500 | — | 4,000 | — | — | 4,000 | |
| Issue stock for employee stock purchase plan | 500 | — | 13,000 | — | — | 13,000 | |
| Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes | 200 | — | (3,000) | — | — | (3,000) | |
| Net loss | — | — | — | (112,017,000) | — | (112,017,000) | |
| Other comprehensive income | — | — | — | — | 4,000 | 4,000 | |
| Balance at December 31, 2024 | 1,865,400 | $— | $728,573,000 | $(693,225,000) | $27,000 | $35,375,000 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.